Loading provider…
Loading provider…
Hematology & Oncology Physician in Nashville, TN
NPI: 1437206232Primary Practice Location
VANDERBILT UNIVERSITY MEDICAL CENTER
2200 Childrens Way, Nashville, TN
Primary Employer
Vanderbilt Health Clinicians, LLC
vanderbilthealth.com
HQ Phone
Get MD Kristin's Phone Numberphone_androidMobile
Get MD Kristin's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardTN State Medical License
TN State Medical License
2007 - 2027
AL State Medical License
2020 - 2020

American Board of Internal Medicine
Medical Oncology
University of Missouri School of Medicine
medicine.missouri.edu
Medical School
Until 2005
Vanderbilt University Medical Center
vumc.org
Fellowship • Hematology and Medical Oncology
2008 - 2011
Residency • Internal Medicine
2005 - 2008
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 123 | 210 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 110 | 400 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 38 | 38 |
| 4 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 18 | 51 |
| 5 | 99222Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 11 | 11 |
Authors: Daniel George, Landon Brown, Kerry Schaffer, Michael Harrison, Matthew Tucker, Wendy Rathmell, Hesham Yasin
Journal: Cancers (Basel)
Publication Date: 2022-08-07
Authors: Zeynep Eroglu, Alexander Shoushtari, Allison Betof Warner, Andrew Brohl
Journal: Ann Oncol
Correlates of response and outcomes with talimogene laherperpvec.
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: BIOLOGICAL: Nivolumab, BIOLOGICAL: Ipilimumab, PROCEDURE: Biospecimen Collection, OTHER: Quality-of-Life Assessment, PROCEDURE: Computed Tomography, PROCEDURE: Multigated Acquisition Scan, DRUG: Trametinib Dimethyl Sulfoxide, PROCEDURE: Echocardiography Test, DRUG: Dabrafenib Mesylate
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Laboratory Biomarker Analysis, OTHER: Pharmacological Study, DRUG: Trametinib, DRUG: Uprosertib
Lead Sponsor: National Cancer Institute (NCI)
Collaborators: Memorial Sloan Kettering Cancer Center, Institut Curie Paris, Moffitt Cancer Center P2C
Intervention / Treatment: DRUG: Vorinostat, OTHER: Laboratory Biomarker Analysis